<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04739241</url>
  </required_header>
  <id_info>
    <org_study_id>14/11</org_study_id>
    <nct_id>NCT04739241</nct_id>
  </id_info>
  <brief_title>Premixed vs Basal Bolus Insulin Therapy in Older Patients With Type 2 Diabetes</brief_title>
  <official_title>Is Premixed Insulin Therapy an Alternative to Basal Bolus Therapy in Type 2 Diabetes Mellitus People Older Than 65 Years Old: A Pilot Randomised Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Consorci Sanitari Integral</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Consorci Sanitari Integral</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare efficacy and security of premixed insulin treatment&#xD;
      vs basal bolus insulin treatment in older patients with poorly controlled type 2 diabetes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 24, 2014</start_date>
  <completion_date type="Actual">June 19, 2018</completion_date>
  <primary_completion_date type="Actual">April 20, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c levels</measure>
    <time_frame>12 months after recruitment</time_frame>
    <description>Change from baseline in HbA1c levels after 12 months of therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of hypoglycaemia as an adverse effect of the treatment</measure>
    <time_frame>every month during the 12-month follow-up</time_frame>
    <description>Number of hypoglycaemias by month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of dosing errors as a measure of the safety of the treatment</measure>
    <time_frame>every month during the 12-month follow-up</time_frame>
    <description>Number of dosing errors by month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the scores of the Diabetes Treatment Satisfaction Questionnaire (DTSQ) from recruitment to month 12.</measure>
    <time_frame>12-month follow-up</time_frame>
    <description>Change from baseline to12 months of therapy using the DTSQ questionnaire of satisfactions with the treatment of diabetes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the scores of the Diabetes Quality Of Life Questionnaire (EsDQOL) from recruitment to month 12.</measure>
    <time_frame>12-month follow-up</time_frame>
    <description>Change from baseline to12 months of therapy using the EsDQOL questionnaire of quality of life in diabetic patients</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Type 2 Diabetes Treated With Insulin</condition>
  <arm_group>
    <arm_group_label>Group A (experimental arm)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Premixed insulin therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (active comparator)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Basal bolus insulin therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>premixed insulin therapy</intervention_name>
    <description>Premixed insulin treatment: 30% of the calculated dose was administered before breakfast and before lunch (biphasic insulin lispro 50% or biphasic insulin aspart 50%) and the remaining 40% of the dose before dinner (biphasic insulin lispro 25% or biphasic insulin aspart insulin 30%).</description>
    <arm_group_label>Group A (experimental arm)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>basal bolus insulin therapy</intervention_name>
    <description>Basal-bolus insulin treatment: 50% dose in insulin glargine and 50% dose in insulin lispro or aspartic, distributed in equal parts in the 3 main meals</description>
    <arm_group_label>Group B (active comparator)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Outpatients&#xD;
&#xD;
          -  Age ≥ 65 years old&#xD;
&#xD;
          -  Type 2 diabetes mellitus&#xD;
&#xD;
          -  HbA1c ≥9% (74 mmol/mol)&#xD;
&#xD;
          -  Previously treated with one or two doses of basal insulin and oral hypoglycaemic&#xD;
             agents&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe insulin-resistance&#xD;
&#xD;
          -  High doses of corticosteroids&#xD;
&#xD;
          -  Chemotherapy treatment&#xD;
&#xD;
          -  High comorbidity&#xD;
&#xD;
          -  Bad compliance of the treatment&#xD;
&#xD;
          -  Frequent severe hypoglycaemia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>January 27, 2021</study_first_submitted>
  <study_first_submitted_qc>February 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2021</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>premixed insulin therapy</keyword>
  <keyword>basal-bolus insulin therapy</keyword>
  <keyword>type 2 diabetes</keyword>
  <keyword>elderly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

